Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
DocMorris AG's 3-Year RORE % for the quarter that ended in Jun. 2025 was 105.82%.
The industry rank for DocMorris AG's 3-Year RORE % or its related term are showing as below:
XSWX:DOCM's 3-Year RORE % is ranked better than 91.1% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 0.74
vs XSWX:DOCM: 105.82
DocMorris AG (XSWX:DOCM) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
DocMorris AG 3-Year RORE % Related Terms
DocMorris AG 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for DocMorris AG's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, DocMorris AG's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocMorris AG 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocMorris AG's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where DocMorris AG's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2025 and 3-year before.
DocMorris AG (XSWX:DOCM) has a 3-Year RORE % of 105.82 as of Jun. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on DocMorris AG and its competitors. According to the industry distribution chart, DocMorris AG ranks #54 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 8.9%.
Is DocMorris AG's 3-Year RORE % too high?
DocMorris AG's current 3-Year RORE % is 105.82. The Healthcare Providers & Services industry median 3-Year RORE % is 0.74. DocMorris AG's value of 105.82 is 14200% above this industry median. Based on the distribution chart, DocMorris AG ranks #54 out of 607 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DocMorris AG has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's 3-Year RORE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DocMorris AG ranks #54 out of 607 companies for 3-Year RORE %. This places DocMorris AG in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 0.74. DocMorris AG's value of 105.82 is 14200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.74, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocMorris AG's current 3-Year RORE % of 105.82 is 14200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on DocMorris AG and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocMorris AG's current 3-Year RORE % is 105.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (XSWX:DOCM) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF10.53, compared to a current price of CHF7.92 — trading 24.8% below its estimated fair value. The current 3-Year RORE % is 105.82 and 14200% above the Healthcare Providers & Services industry median of 0.74. DocMorris AG's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For DocMorris AG (XSWX:DOCM), the current 3-Year RORE % is 105.82 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocMorris AG (XSWX:DOCM) Overvalued in 2026?
Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued.
The current stock price of CHF7.92 is trading 24.8% below its estimated GF Value™ of CHF10.53.
GuruFocus considers DocMorris AG to be Modestly Undervalued.
Key valuation signals for XSWX:DOCM:
3-Year RORE %: 105.82
GF Value™: CHF10.53 vs. price of CHF7.92 (24.8% below fair value)
Industry Position: 14200% above the Healthcare Providers & Services median (#54 of 607)
No single metric tells the full story. See the XSWX:DOCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
65GF Score
Get the complete analysis for XSWX:DOCM
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DOCM has been successfully added to your 
